First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. (Q53607758)

16 May 2018

title

First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. (English)

1 reference

16 May 2018

author name string

Patricia M LoRusso

1

1 reference

16 May 2018

Priscila H Goncalves

2

1 reference

16 May 2018

Lindsay Casetta

3

1 reference

16 May 2018

Judith A Carter

4

1 reference

16 May 2018

Kevin Litwiler

5

1 reference

16 May 2018

Dale Roseberry

6

1 reference

16 May 2018

Selena Rush

7

1 reference

16 May 2018

Jennifer Schreiber

8

1 reference

16 May 2018

Heidi M Simmons

9

1 reference

16 May 2018

Mieke Ptaszynski

10

1 reference

16 May 2018

Edward A Sausville

11

1 reference

16 May 2018

publication date

17 February 2015

1 reference

16 May 2018

Investigational New Drugs

published in

1 reference

16 May 2018

volume

33

1 reference

16 May 2018

issue

2

1 reference

16 May 2018

page(s)

440-449

1 reference

16 May 2018

https://scigraph.springernature.com/pub.10.1007/s10637-015-0211-0

exact match

0 references

cites work

Mitotic drug targets and the development of novel anti-mitotic anticancer drugs

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Microtubule active agents: beyond the taxane frontier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Mitosis as an anti-cancer target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Targeting the kinesin spindle protein: basic principles and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Development of new cancer therapeutic agents targeting mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Regulation of microtubule dynamics by kinesins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

The way things move: looking under the hood of molecular motor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Kinesin-5: cross-bridging mechanism to targeted clinical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Antitumor activity of a kinesin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Kinesin motor proteins as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Myeloid cell factor-1 is a critical survival factor for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

"A fortuitous combination of circumstances".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0211-0

ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25684345

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Lack of tension at kinetochores activates the spindle checkpoint in budding yeast

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25684345

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-015-0211-0

1 reference

16 May 2018

1 reference

16 May 2018